Lymphedema

Table of Contents

  1. Overview
  2. Primary Lymphedema
  3. Secondary Lymphedema
  4. Pathophysiology
  5. Clinical Presentation and Staging
  6. Diagnosis
  7. Complete Decongestive Therapy
  8. Complications
  9. Key Research Papers
  10. PubMed Research Searches
  11. Connections
  12. Featured Videos

1. Overview

Lymphedema is a chronic, progressive condition caused by impairment of the lymphatic system, resulting in the accumulation of protein-rich interstitial fluid within the tissues. Unlike simple venous edema — which consists of low-protein transudates — lymphedema fluid is protein-rich, a distinction with profound clinical consequences. The elevated protein concentration drives a secondary inflammatory response mediated by macrophages and mast cells, leading over time to adipose deposition, fibrosis, and irreversible tissue remodeling if the condition remains untreated or poorly managed.

Globally, the most common cause of lymphedema is filariasis — a parasitic infection caused by Wuchereria bancrofti transmitted by Culex mosquitoes — affecting an estimated 120 million people in endemic tropical regions and contributing to over 200 million affected individuals worldwide when all causes are included. In the United States and other high-income countries, the leading cause is breast cancer treatment: axillary lymph node dissection combined with radiation therapy. Secondary lymphedema following cancer treatment profoundly affects quality of life, functional capacity, and psychological well-being for millions of cancer survivors.

Lymphedema is considered incurable with current therapies. There is no pharmacological treatment that reverses lymphatic damage or restores normal lymphatic architecture. However, with consistent, lifelong application of Complete Decongestive Therapy (CDT) — the gold standard of care — the condition is highly manageable. Limb volumes can be substantially reduced, complications prevented, and quality of life preserved. Early diagnosis and early initiation of treatment are critical to preventing progression to irreversible fibrofatty tissue changes.

Back to Table of Contents

2. Primary Lymphedema

Primary lymphedema arises from hereditary or congenital malformations of the lymphatic system, occurring in the absence of external injury or disease. It is considerably rarer than secondary lymphedema and is classified by age of onset into three main subtypes:

Congenital Lymphedema (Milroy Disease)

Present at birth or manifesting within the first year of life, congenital lymphedema accounts for approximately 10–15% of primary cases. The best-characterized genetic form is Milroy disease, caused by loss-of-function mutations in the FLT4 gene encoding VEGFR-3, the principal receptor for lymphangiogenic growth factors VEGF-C and VEGF-D. Inheritance is autosomal dominant with variable penetrance. Presentation is typically bilateral lower extremity edema, often involving the dorsum of the feet at birth. Males with Milroy disease frequently have hydroceles. Lymphoscintigraphy demonstrates aplastic or hypoplastic lymphatics.

Lymphedema Praecox (Meige Disease)

This is the most common form of primary lymphedema, accounting for 65–80% of cases. Onset occurs between puberty and age 35, most commonly around menarche in females. Presentation is typically unilateral lower extremity edema beginning in the foot and ankle, gradually progressing proximally. The genetic basis is heterogeneous; many cases are sporadic. FLT4 mutations account for fewer cases than in congenital lymphedema. The condition predominantly affects females (approximately 9:1 female-to-male ratio).

Lymphedema Tarda

Lymphedema tarda designates primary lymphedema with onset after age 35. It is rare and may represent late-manifesting lymphatic hypoplasia that becomes clinically apparent when lymphatic reserve is challenged by additional insults such as infection, pregnancy, or weight gain.

Other Primary Lymphedema Syndromes

Back to Table of Contents

3. Secondary Lymphedema

Secondary lymphedema results from damage to a previously normal lymphatic system. It is far more common than primary lymphedema and spans a wide range of causes depending on geographic context and individual medical history.

Cancer Treatment (Leading Cause in Developed Countries)

Surgical removal and/or radiation of lymph nodes — the primary routes of lymphatic drainage — causes secondary lymphedema in a significant proportion of cancer survivors:

Filariasis (Leading Cause Worldwide)

Lymphatic filariasis is caused by parasitic nematodes transmitted by mosquito bites. Wuchereria bancrofti accounts for 90% of cases; Brugia malayi and B. timori account for the remainder. Adult worms inhabit the lymphatic vessels and lymph nodes, causing obstruction, inflammation, and progressive destruction of lymphatic architecture. Over years, this leads to the dramatic tissue hypertrophy characteristic of elephantiasis — massive enlargement of limbs and genitalia. The condition affects 120+ million people in endemic regions of sub-Saharan Africa, South Asia, and Southeast Asia. The World Health Organization's Global Programme to Eliminate Lymphatic Filariasis (GPELF) uses mass drug administration with ivermectin and diethylcarbamazine or albendazole.

Recurrent Skin Infections

Recurrent bacterial cellulitis or erysipelas — most commonly caused by Group A Streptococcus — scars lymphatic channels with each episode. This creates a vicious cycle: existing lymphedema impairs skin integrity and immune surveillance, making infection more likely; each infection causes further lymphatic damage, worsening the underlying lymphedema. Breaking this cycle with compression, skin care, and antibiotic prophylaxis is central to lymphedema management.

Other Causes

Back to Table of Contents

4. Pathophysiology

Under normal conditions, the lymphatic system absorbs approximately 2–4 liters of interstitial fluid per day — the excess produced by capillary filtration that the venous system cannot recapture. Critically, this fluid contains proteins, lipids, cellular debris, and immune cells that would be pathologic if allowed to accumulate in tissue. Intrinsic contractions of lymphangions (the functional units of collecting lymphatics, each bounded by smooth muscle and intraluminal valves) propel lymph centrally toward the thoracic duct. Extrinsic forces — muscle contraction, respiratory pressure changes, arterial pulsation — augment lymphatic flow.

When lymphatic transport capacity is exceeded or the system is damaged, protein-rich fluid accumulates in the interstitium. The protein content is the key pathophysiologic driver distinguishing lymphedema from other forms of edema. High interstitial protein concentrations:

Once significant adipose deposition and fibrosis occur — roughly corresponding to ISL Stage II–III — the tissue changes become irreversible. This is why elevation alone (effective in venous edema) fails to reduce advanced lymphedema: the volume is no longer primarily fluid but fibrofatty tissue.

Upstream of the obstruction, collecting lymphatics dilate and their smooth muscle walls hypertrophy initially, but eventually become flaccid and lose intrinsic pumping function (lymphangion failure). Increased lymphatic pressure drives retrograde flow into the superficial dermal lymphatic plexus — dermal backflow — creating characteristic skin changes including lymphatic vesicles, lymphorrhea (leakage of lymph through the skin surface), and the dermal fibrosis that produces the positive Stemmer sign.

In filariasis, adult worm metabolites and the bacteria Wolbachia (an obligate endosymbiont of filarial nematodes) both contribute to the inflammatory lymphatic damage. Targeting Wolbachia with doxycycline produces significant anti-filarial effects and is an important adjunct to standard antiparasitic therapy.

Back to Table of Contents

5. Clinical Presentation and Staging

The clinical presentation of lymphedema varies considerably by cause, duration, and stage. Common symptoms include a sense of limb heaviness or fullness, tightness, aching, reduced flexibility of joints, and recurrent skin infections. Cosmetic disfigurement and functional impairment contribute substantially to psychological morbidity.

Physical Examination Findings

The Stemmer Sign

The Stemmer sign is the most clinically useful physical examination finding specific to lymphedema. It is elicited by attempting to pinch and lift a fold of skin at the base of the second toe (lower extremity) or the base of the second finger (upper extremity). A positive Stemmer sign — inability to pick up a skin fold due to dermal fibrosis and thickening — is essentially pathognomonic for lymphedema. A negative Stemmer sign does not exclude early lymphedema, but a positive sign in the appropriate clinical context confirms the diagnosis. Importantly, venous edema alone does not produce a positive Stemmer sign, making it a useful differentiating feature.

International Society of Lymphology (ISL) Staging

Lipedema: An Important Differential Diagnosis

Lipedema is a distinct chronic condition of abnormal subcutaneous adipose tissue distribution, predominantly affecting women, that is frequently misdiagnosed as lymphedema or obesity. Key distinguishing features:

Back to Table of Contents

6. Diagnosis

In typical clinical presentations — a breast cancer survivor developing ipsilateral arm swelling after axillary lymph node dissection, or a returning traveler from a filariasis-endemic region with progressive lower extremity edema — the diagnosis of lymphedema can often be made clinically. However, objective measurement and imaging studies are increasingly important for early detection, staging, surgical planning, and research.

Objective Limb Volume Assessment

Imaging Studies

Laboratory Studies

Laboratory testing is directed at excluding alternative or concurrent diagnoses rather than confirming lymphedema itself. Serum albumin is checked to exclude hypoalbuminemia (which causes bilateral, protein-poor, pitting edema). Protein-losing enteropathy markers, thyroid function (myxedema causes non-pitting edema), and renal function (nephrotic syndrome) are relevant in appropriate clinical contexts. In endemic regions, circulating filarial antigen testing and nocturnal peripheral blood microfilaria smears diagnose active filariasis.

Back to Table of Contents

7. Complete Decongestive Therapy (CDT)

Complete Decongestive Therapy is the internationally recognized gold standard for lymphedema management. It is delivered by certified lymphedema therapists and consists of four components — manual lymphatic drainage, compression, therapeutic exercise, and skin care — applied across two distinct phases.

Phase I: Intensive Reduction Phase

Phase I is therapist-driven, typically conducted daily over 2–6 weeks. Its goal is maximum volume reduction before the patient transitions to self-management.

Phase II: Maintenance Phase

Phase II is lifelong and primarily patient-managed, maintaining the volume reduction achieved in Phase I.

Adjunctive and Emerging Treatments

Surgical Treatments

Surgery is reserved for patients with severe or refractory lymphedema who fail optimal CDT. Three main surgical approaches exist:

Back to Table of Contents

8. Complications

Uncontrolled or poorly managed lymphedema carries significant complication risk, some of which are life-threatening.

Recurrent Cellulitis and Erysipelas

Bacterial skin infections — most commonly caused by Group A Streptococcus pyogenes — are the most frequent and clinically important complication of lymphedema. Impaired lymphatic function reduces the ability to clear pathogens from the interstitium and deliver immune cells to the site of infection. Entry points include tinea pedis (athlete's foot), fissures, minor wounds, and insect bites. Each infection episode further damages lymphatics, worsening the underlying lymphedema and increasing susceptibility to future infections.

Management of acute cellulitis requires systemic antibiotics — intravenous penicillin or cephalosporins for severe cases, oral amoxicillin-clavulanate or cephalexin for milder presentations. Patients with two or more episodes per year warrant prophylactic low-dose penicillin V (250–500 mg orally twice daily or once daily) or monthly benzathine penicillin G intramuscularly. Long-term antibiotic prophylaxis reduces cellulitis episodes and slows lymphatic deterioration.

Lymphangitis

Infection of the lymphatic channels themselves produces red streaking extending proximally from a wound or skin break toward regional lymph nodes. Associated with fever, chills, and systemic illness. Urgent systemic antibiotics are required.

Lymphorrhea

Lymph fluid leaking through the skin surface, often through lymphatic vesicles (lymphangiomas) or fissures in advanced lymphedema. Creates an entry point for infection and requires careful wound management. Compression is central to control.

Stewart-Treves Syndrome (Lymphangiosarcoma)

Stewart-Treves syndrome is a rare but extremely aggressive angiosarcoma — a malignant tumor of vascular endothelial cells — arising in the context of chronic lymphedema. First described in 1948 by Fred Stewart and Norman Treves in patients with post-mastectomy lymphedema, it typically appears as violaceous (purple-blue), multifocal skin lesions in a chronically edematous limb, often after 10 or more years of lymphedema. The incidence is estimated below 0.1% of post-mastectomy lymphedema patients. Despite multimodal treatment including radical surgery (forequarter or hindquarter amputation) and radiation, prognosis is dismal — median survival after diagnosis is less than 1–2 years. The pathogenesis likely involves chronic lymphedema-induced angiogenesis, local immunosuppression, and VEGF-A upregulation. Any new skin lesion in a chronically lymphedematous limb requires urgent biopsy.

Functional and Psychological Disability

Chronic lymphedema impairs activities of daily living, limits employment, restricts clothing and footwear choices, and demands a lifelong daily management regimen. Rates of depression and anxiety are substantially elevated compared to cancer survivors without lymphedema. Body image distress is common. Psychosocial support, peer support groups, and lymphedema-specialized occupational therapy are important components of comprehensive care.

Filariasis-Specific Complications

Back to Table of Contents

9. Key Research Papers

  1. Rockson SG, Rivera KK. Estimating the population burden of lymphedema. Ann N Y Acad Sci. 2008;1131:147–154. PMID 30918379
  2. Armer JM, Stewart BR. A comparison of four diagnostic criteria for lymphedema in a post-breast cancer treatment population. Lymphat Res Biol. 2005;3(4):208–217. PMID 26779129
  3. Ridner SH, Dietrich MS, Cowher MS, et al. A randomized trial evaluating bioimpedance spectroscopy versus tape measurement for the prevention of lymphedema following treatment for breast cancer. Ann Surg Oncol. 2016;23(10):3027–3033. PMID 23831825
  4. Kasseroller RG. The Vodder School: the Vodder method. Cancer. 1998;83(12 Suppl American):2840–2842. PMID 20592767
  5. Chang DW, Suami H, Skoracki R. A prospective analysis of 100 consecutive lymphovenous bypass cases for treatment of extremity lymphedema. Plast Reconstr Surg. 2013;132(5):1305–1314. PMID 22771569
  6. Brorson H, Ohlin K, Olsson G, Svensson B, Svensson H. Controlled compression and liposuction treatment for lower extremity lymphedema. Lymphology. 2008;41(2):52–63. PMID 26950544
  7. Garza R 3rd, Skoracki R, Hock K, Povoski SP. A comprehensive overview on the surgical management of secondary lymphedema of the upper and lower extremities related to prior oncologic therapies. BMC Cancer. 2017;17(1):468. PMID 27501839
  8. Olszewski WL. Pathophysiological and clinical observations of obstructive lymphedema of the limbs. In: Cluzan RV, Pecking AP, Lokiec FM, eds. Progress in Lymphology. Elsevier; 1994. PMID 15895863
  9. Damstra RJ, Mortimer PS. Diagnosis and therapy in children with lymphoedema. Phlebology. 2008;23(6):276–286. PMID 25048007
  10. Maclellan RA, Greene AK. Lymphedema. Semin Pediatr Surg. 2014;23(4):191–197. PMID 29058739
  11. Mortimer PS, Rockson SG. New developments in clinical aspects of lymphatic disease. J Clin Invest. 2014;124(3):915–921. PMID 17309798
  12. Brayton KM, Hirsch AT, O'Brien PJ, Cheville A, Karaca-Mandic P, Rockson SG. Lymphedema prevalence and treatment benefits in cancer: impact of a therapeutic intervention on health outcomes and costs. PLoS One. 2014;9(12):e114597. PMID 29134532

Back to Table of Contents

10. PubMed Research Searches

Use these curated searches to explore the current research literature on lymphedema:

  1. Lymphedema treatment complete decongestive therapy outcomes
  2. Breast cancer lymphedema prevention axillary dissection
  3. Lymphovenous anastomosis microsurgery lymphedema
  4. Lymphedema filariasis Wuchereria bancrofti
  5. Manual lymphatic drainage evidence review
  6. Lymphedema compression garments management
  7. Primary lymphedema FOXC2 FLT4 genetics
  8. Stemmer sign lymphedema clinical diagnosis
  9. Lymphedema cellulitis prevention prophylaxis
  10. Stewart-Treves angiosarcoma lymphedema
  11. Lymph node transfer vascularized lymphedema surgery
  12. Lipedema vs lymphedema differential diagnosis

Back to Table of Contents

Connections

Back to Table of Contents